Company to view next
Generic selectors
Exact matches only
Search in title
Search in content

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

11

Address:

ARCA biopharma, Inc. 10170 Church Ranch Way Suite 100 Westminster CO 80021 United States

Website:

Home Page

Phone:

720-940-2200

Leave a comment

Your email address will not be published. Required fields are marked *